G protein-coupled receptor

Related people (32)

Kristina Schoonjans

Johan Auwerx

Johan Auwerx is Professor at the École Polytechnique Fédérale in Lausanne, Switzerland, where he occupies the Nestle Chair in Energy Metabolism. Dr. Auwerx has been using molecular physiology and systems genetics to understand metabolism in health, aging and disease. Much of his work focused on understanding how diet, exercise and hormones control metabolism through changing the expression of genes by altering the activity of transcription factors and their associated cofactors. His work was instrumental for the development of agonists of nuclear receptors - a particular class of transcription factors - into drugs, which now are used to treat high blood lipid levels, fatty liver, and type 2 diabetes. Dr. Auwerx was amongst the first to recognize that transcriptional cofactors, which fine-tune the activity of transcription factors, act as energy sensors/effectors that influence metabolic homeostasis. His research validated these cofactors as novel targets to treat metabolic diseases, and spurred the clinical use of natural compounds, such as resveratrol, as modulators of these cofactor pathways. Johan Auwerx was elected as a member of EMBO in 2003 and is the recipient of a dozen of international scientific prizes, including the Danone International Nutrition Award, the Oskar Minkowski Prize, and the Morgagni Gold Medal. His work is highly cited by his peers with a h-factor of over 100. He is an editorial board member of several journals, including Cell Metabolism, Molecular Systems Biology, The EMBO Journal, Journal of Cell Biology, Cell, and Science. Dr. Auwerx co-founded a handful of biotech companies, including Carex, PhytoDia, and most recently Mitobridge, and has served on several scientific advisory boards. Dr. Auwerx received both his MD and PhD in Molecular Endocrinology at the Katholieke Universiteit in Leuven, Belgium. He was a post-doctoral research fellow in the Departments of Medicine and Genetics of the University of Washington in Seattle.

Rudolf Hovius

Gerardo Turcatti

Senior scientific level (R&D) with extensive experience in the management of multidisciplinary technological projects. Prof. Gerardo Turcatti, directs the academic technological platform, Biomolecular Screening Facility (BSF) at the EPFL he created in 2006. In the framework of the NCCR-Chemical Biology, he is project leader of the program ACCESS (An Academic Chemical Screening Platform for Switzerland). Previously he co-founded and acted as CTO of Manteia S.A., a Swiss-based company that developed high throughput DNA sequencing technologies currently owned by Illumina and used in the ‘Next Generation Sequencing’ instruments. Prior to this experience, Prof. Turcatti had a long multidisciplinary career in R&D divisions of Biotechnology and Pharmaceutical companies with extensive expertise in several Chemical Biology-related disciplines such as Drug Screening, Chemical Biology, Bio-analytical Chemistry, DNA and Protein Chemistry. Prof. Turcatti earned his Master in Chemical Engineering at the University of Geneva and his PhD in Chemistry and Biochemistry from the EPFL where he received the award for the best doctoral thesis of the year.

Patrick Daniel Barth

Professor Patrick Barth is Associate Professor at EPFL and Adjunct Associate Professor at Baylor College of Medicine, Houston, TX, USA. He received training in Physics, Chemistry and Biology (University of Paris, ENS) in France and performed his PhD at the Commissiariat a l'Energie Atomique in Saclay, France on structure/function studies of membrane proteins (photosystem I) using biochemical and biophysical experimental techniques. He carried out postdoctoral studies at University of California at Berkeley with Tom Alber on computational development for calculating protein electrostatics and designing de novo selective peptide inhibitors of cellular protein interactions. He then went to the University of Washington as a postdoctoral fellow and instructor in David Baker's laboratory to develop computational techniques in the software Rosetta for predicting and designing membrane protein structures. He started his independent career and received tenure at Baylor College of Medicine. He will continue at EPFL to marry computation and experiment for understanding the molecular determinants of signal transduction, as well as modeling and designing membrane proteins with novel functions for various synthetic biology and therapeutic applications.

Horst Pick

Ursula Röthlisberger

U. Röthlisberger was born in Solothurn (Switzerland). In 1988 she made her diploma in Physical Chemistry in the group of Prof. Ernst Schumacher at the University of Berne (Switzerland). Her Ph.D. thesis was done in collaboration with Dr. Wanda Andreoni at the IBM Zurich Research Laboratory in Rüschlikon. After finishing her Ph.D in 1991 she spent some time as a postdoctoral research assistant at the IBM Research Lab. From 1992-1995 she was a postdoctoral research assistant in the group of Prof. Michael L. Klein at the University of Pennsylvania in Philadelphia (USA). In 1994 she was awarded an advanced researcher fellowship (Profil 2) from the Swiss National Science Foundation. Before starting her Profile 2-fellowship she spent another year as postdoctoral research assistant in the group of Prof. Michele Parrinello at the Max-Planck-Institute for Solid State Physics in Stuttgart, Germany. In 1996 she moved as Profile 2-fellow to the ETH in Zurich, hosted by the group of Prof. Wilfred F. van Gunsteren. In 1997 she became Assistant Professor of Computer-Aided Inorganic Chemistry at the ETH Zurich.

Kai Johnsson

Henning Paul-Julius Stahlberg

Nikolaos Stergiopulos

Education MTE, Managing the Technology Enterprise Program (2000), IMD, Lausanne Ph.D. in Biomedical Engineering & Engineering Mechanics (1990) Iowa State University, Ames, Iowa. MS in Biomedical Engineering (1987) Iowa State University, Ames, Iowa. Diploma in Mechanical Engineering (1985) National Technical University of Athens. Professional Activities 2002 - present: Professor and director of LHTC 2010 - present: Founder and director of Rheon Medical SA, Préverenges, Switzerland 2008 - present: Founder and director of Antlia S.A., PSE-C, EPFL campus, Switzerland 1998 - 2007: Founder and Scientific Director of EndoArt S.A., Lausanne, Switzerland 1996 - 2002: Assistant professor at the Biomedical Engineering Laboratory, Swiss Federal Institute of Technology, Lausanne, Switzerland. 1991 - 1996: Research Associate at Swiss Federal Institute of Technology - Lausanne 1990 - 1991: Lecturer, Iowa State University